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Abstract
Left ventricular (LV) remodelling after myocardial infarction (MI) is a crucial determinant of the clinical course of heart failure. Matrix metallo-
proteinase (MMP) activation is strongly associated with LV remodelling after MI. Elucidation of plasma membrane receptors related to the acti-
vation of specific MMPs is fundamental for treating adverse cardiac remodelling after MI. The aim of current investigation was to explore the
potential association between the low-density lipoprotein receptor-related protein 1 (LRP1) and MMP-9 and MMP-2 spatiotemporal expression
after MI. Real-time PCR and Western blot analyses showed that LRP1 mRNA and protein expression levels, respectively, were significantly
increased in peri-infarct and infarct zones at 10 and 21 days after MI. Confocal microscopy demonstrated high colocalization between LRP1
and the fibroblast marker vimentin, indicating that LRP1 is mostly expressed by cardiac fibroblasts in peri-infarct and infarct areas. LRP1 also
colocalized with proline-rich tyrosine kinase 2 (pPyk2) and MMP-9 in cardiac fibroblasts in ischaemic areas at 10 and 21 days after MI. Cell cul-
ture experiments revealed that hypoxia increases LRP1, pPyk2 protein levels and MMP-9 activity in fibroblasts, without significant changes in
MMP-2 activity. MMP-9 activation by hypoxia requires LRP1 and Pyk2 phosphorylation in fibroblasts. Collectively, our in vivo and in vitro data
support a major role of cardiac fibroblast LRP1 levels on MMP-9 up-regulation associated with ventricular remodelling after MI.
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Introduction
Adverse myocardial remodelling is associated with poor patient out-
comes in the setting of ischaemic heart disease and/or MI, cardiac
hypertrophy and cardiomyopathy disease processes [1–3]. In particu-
lar, adverse cardiac remodelling after MI causes ventricular functional
impairment and heart failure (HF). The incidence of HF after MI is
determined by infarct area size, infarct wound healing and chronic LV
remodelling [4–6].
Cardiomyocyte apoptosis and necrosis involving infarcted regions
and residual viable myocardium trigger a cascade of immune-inflam-
matory pathways and cellular mechanisms that promote wound
healing and a unique pattern of LV structural remodelling-related
changes [7–9]. During its early phases, LV remodelling occurs sec-
ondary to thinning and dilation of the infarcted myocardial wall (in-
farct expansion). During its late phases, LV remodelling occurs
secondary to architectural rearrangements of the surviving myocar-
dium characterized by myocyte hypertrophy, interstitial fibrosis and
LV dilation [4, 5]. Perivascular fibrosis impairs myocyte oxygen avail-
ability, reduces coronary reserve and exacerbates myocardial ischae-
mia [10]. LV remodelling thus plays a central role in clinical
progression to HF. The identification of new receptors involved in LV
remodelling has opened the door for finding new therapeutic targets
for treating HF. Low-density LRP1 is a lipoprotein receptor up-regu-
lated by hypoxia in human vascular smooth muscle cells (hVSMCs)
[11, 12] and cardiomyocytes [13, 14]. LRP1 was strongly up-regu-
lated in ischaemic myocardial tissue in a porcine model of acute MI
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[13, 14] and in ischaemic cardiomyopathy patients [13, 14]. LRP1
plays a crucial role in regulating MMP-9 and MMP-2 expression [15–
17] and mediates MMP-9 cellular catabolism to regulate its extracel-
lular levels [18, 19]. Our group recently demonstrated that LRP1
modulates MMP-9 expression and activation in hVSMCs exposed to
hypoxia through Pyk2 phosphorylation [12]. It is known that MMP-9
plays a key role in MI-related cardiac remodelling and adverse out-
comes [20, 21]; however, neither LRP1 spatiotemporal expression
nor the relationship between LRP1 and MMP-9 expression during the
evolution of adverse myocardial remodelling has been previously
investigated. The aim of current investigation was to explore the
potential relationship between cardiac LRP1 spatiotemporal expres-
sion after MI and MMP-9 and MMP-2 expression and activation.
Materials and methods
Mouse model of MI
A total of 46 male C57/Bl6 mice 12–13 weeks of age (25–30 g; Charles
River Laboratories, Inc.; Wilmington, MA) were used in this study. MI
was induced as previously described [22]. Briefly, each animal was intu-
bated and anesthetized with a mixture of O2/isoflurane and was
mechanically ventilated. The heart was exposed, and the left anterior
descending coronary artery was permanently occluded. The animals
were sacrificed at 1 day (n = 17), 10 days (n = 14) and 21 days
(n = 15) after operation, and their hearts were excised and frozen in liq-
uid nitrogen for molecular and lipid analyses. Six animals from each
group were processed for histological analysis; their hearts were
arrested during diastole using cardioplegic solution (68.4 mM NaCl,
59 mM KCl, 11.1 mM glucose, 1.9 mM NaHCO3, 29.7 mM 2,3-butane-
dione monoxime, 1000 U heparin), excised, fixed, cryopreserved in
30% sucrose in phosphate-buffered saline, embedded in Tissue-Tek
O.C.T. (Sakura) and snap-frozen in liquid nitrogen-cooled isopentane for
histological evaluation. All animal handling procedures were approved
by the Institutional Animal Care and Use Committee and conformed to
the Guide for the Care and Use of Laboratory Animals of the Institute of
Laboratory Animal Research (NIH Pub. No. 86-23, Revised 1996).
Macrophage cell culture
Monocyte-derived macrophages were isolated by standard protocols from
buffy coats (35–40 ml) of healthy donors. This protocol complied with
the Declaration of Helsinki and was approved by the local institutional
committee on human research. Cells were applied on 15 ml of Ficoll–
Hypaque and centrifuged at 4009g for 40 min. at 22°C, with no brake.
Mononuclear cells were obtained from the central white band of the gradi-
ent, exhaustively washed in PBS and resuspended in RPMI medium sup-
plemented with 10% human AB serum, 1% P/S and 1% HEPES. Cells
were allowed to differentiate into macrophages by exposure to 10%
human AB serum for 7 days, changing the medium every other day.
Fibroblast cell culture
Control (Lrp1+/+, MEF, CRL-2214) and LRP1-deficient fibroblasts
(Lrp1/, PEA13, CRL-2216) fibroblasts were obtained from American
Type Culture Collection. Lrp1+/+ and Lrp1/ were grown in DMEM sup-
plemented with 10% foetal calf serum, 2 mM L-glutamine, 100 U/ml
penicillin G and 100 lg/ml streptomycin, as previously described [23].
The cells were exposed to hypoxia (1% O2) in an H35 Hypoxic/Anoxic
Workstation (Don Whitley Scientific Ltd.; West Yorkshire, UK) with 94%
N2 and 5% CO2. The cells were then harvested via scraping in TriPure
TM
Isolation Reagent (Roche Molecular Diagnostics; Indianapolis, USA) for
PCR and Western blot analysis, and the cell culture supernatants were
collected for zymography studies.
Cell exposure to normoxic and hypoxic
conditions
Macrophages and fibroblasts (Lrp1+/+ and Lrp1/) were serum-
deprived once they reached 80% confluence. Cells were exposed to nor-
moxia (21% O2) in an incubator with gas mixtures consisting of 74%
N2 and 5% CO2 or to hypoxia (1% O2) in a Hypoxic/Anoxic Workstation:
H35 (Don Whitley Scientific Ltd.) with 94% N2 and 5% CO2. Cells were
then harvested by scraping in TriPureTM Isolation Reagent (Roche
Molecular Diagnostics) for Western blot analysis. Culture supernatants
were finally collected for zymographic studies.
RNA extraction and cDNA synthesis
Frozen cardiac tissue samples were pulverized using a mortar and a pestle
in liquid nitrogen to maintain RNA integrity. Cardiac tissue (40 mg) was
weighed, and total RNA was isolated using TriPureTM Isolation Reagent
(Roche Molecular Diagnostics, Indianapolis, USA), according to the
manufacturer’s instructions. RNA yield and quality were assessed by 1%
agarose gel electrophoresis, and then the RNA was stored at 80°C until
analysis. Reverse transcription was performed using 1.5 lg of total RNA
and a High-capacity cDNA Reverse Transcription Kit (Applied Biosystems,
Foster City, CA, USA). The cDNA was stored at 20°C.
Gene expression analyses by RT-PCR
Lrp1, Mmp-9 and Mmp-2 mRNA gene expression analyses were per-
formed via semiquantitative real-time reverse-transcriptase polymerase
chain reaction (RT-PCR) using the assays-on-demand listed in Table 1.
Endogenous eukaryotic 18S rRNA expression served as an internal gene
amplification control. RT-PCR was performed using 1 ll of reverse tran-
scription products mixed with 10 ll of TaqMan Universal PCR Master
Mix (Applied Biosystems, Foster City, CA, USA), 1 ll of 209 assays
and 8 ll of nuclease-free water. After gentle mixing, the mixture was
transferred to a real-time PCR microplate.
Table 1 Assays-on-demand used for real-time PCR analysis
Assays Reference Species Company
Lrp1 Mm00464608_m1 Mouse Applied Biosystems
Mmp-9 Rn00675898_m1 Rat Applied Biosystems
Mmp-2 Rn01538169_m1 Rat Applied Biosystems
18s rRNA 4319413E Applied Biosystems
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PCR was performed in a PCR-7600HT sequence detection system
(Abiprism; Applied Biosystems) under the following conditions: 50°C
for 2 min., 95°C for 10 min., 40 cycles at 95°C for 15 sec. and
60°C for 1 min. Relative gene expression levels were quantified and
analysed using SDS 2.4 software, and the real-time values of each
sample were averaged and compared using the CT method, by which
the target RNA expression level (2DDCT) was normalized to that of
an endogenous control (DCT).
Western blotting
Frozen cardiac tissue samples were pulverized using a mortar and a
pestle in liquid nitrogen to maintain protein integrity. Pulverized tis-
sue aliquots (40 mg) were subsequently weighed, and protein was
isolated using TriPureTM Isolation Reagent (Roche Molecular Diagnos-
tics), according to the manufacturer’s instructions. The protein was
quantified using Pierce BCA Protein Assay (Thermo Scientific,
Waltham, MA, USA). Equivalent amounts of total protein (25 or 30 lg)
were loaded onto 10% (v/v) SDS-polyacrylamide gels under reducing
conditions. The samples were then electrotransferred to nitrocellulose
membranes, which were saturated at room temperature for 1 hr in
TTBS (20 mM Tris–HCl, pH 7.5, 500 mM NaCl, 0.01% Tween 20 and
5% non-fat milk). Western blot analyses were performed using specific
monoclonal antibodies (Table 2) and the corresponding secondary
antibodies (1:10,000 dilution; Dako; Glostrup, Denmark).
Equal protein loading was verified via Ponceau staining and Western
blotting for troponin T. Bands were detected using ECL Prime Western
Blotting Detection Reagent (Amersham) and quantified via densitometry
using a ChemiDoc system and Quantity One software (Bio-Rad,
Hercules, CA, USA). The results are expressed as arbitrary units of
intensity.
Gelatin zymography
Relative MMP-9 and MMP-2 activity levels in infarcted myocardium
were measured by zymography. Pulverized tissue aliquots (5 mg) were
weighed, homogenized in 60 ll of lysis buffer [1 M Tris–HCl, pH 8,
1 M KCl supplemented with one tablet of complete protease inhibitor
cocktail (Roche Molecular Diagnostics, IN, USA)], sonicated and cen-
trifuged at 16, 000 9 g for 15 min. The supernatants were subse-
quently quantified via Pierce BCA Protein Assay (Thermo Scientific,
Waltham, MA, USA). Thirty micrograms of protein was then mixed with
69 non-reducing loading buffer, after which the samples were loaded
onto 10% (v/v) SDS-polyacrylamide gels, with 1 mg/ml porcine skin A
gelatin (Sigma-Aldrich , St. Luis, MO, USA) serving as a substrate for
MMP enzymatic activity, and run at 4°C for 4–6 hrs.
After electrophoresis, the gels were rinsed twice in 2.5% Triton X-
100 for 30 min. at room temperature and then incubated in substrate
buffer (50 mM Tris–HCl, 10 mM CaCl2, 0.02% (w/v) N3Na, pH 8) for
18–20 hrs at 37°C. The gels were dyed with 10% acetic acid with
one tablet of PhastGelTM Blue R. Gelatinolytic activity areas, in which
the protease digested the substrate, appeared as clear bands on a
blue background. The gels were ultimately scanned with a GS-800
calibrated imaging densitometer, and quantitative densitometric analy-
sis of the digested bands was performed using Quantity-One soft-
ware (Bio-Rad, Hercules, CA, USA).
Immunofluorescence
Mouse heart cryosections were incubated with primary antibodies
against LRP1 (2 lg/ml; Abcam, Cambridge, UK), cardiac troponin I
(cTnI; 2 lg/ml; Abcam), vimentin (2 lg/ml; Abcam, Cambrigde,
UK), pPky2 (4 lg/ml; Santa Cruz Biotechnology, Dallas, TX, USA),
pERK1,2 (8 lg/ml; Santa Cruz Biotechnology, Dallas, TX, USA),
MMP-9 (20 lg/ml; AMS Biotechnology , Abingdon, UK) and MMP-
2 (20 lg/ml; AMS Biotechnology , Abingdon, UK) (Table 3). These
samples were also stained with biotinylated GSLI B4 isolectin
(Vectors Laboratories) for vessel detection. Cell nuclei were coun-
terstained with 40,6-diamidino-2-phenylindole (DAPI), and the
results were analysed with an Axio Observer Z1 (Zeiss) laser con-
focal microscope.
Statistical analysis
The statistical software package SPSS 15.0 for Windows (SPSS Inc.,
Chicago, IL, USA) was used for all statistical analyses. Data normal-
ity was analysed using the Kolmogorov–Smirnov test. Continuous
variables were compared between groups using one-way ANOVA.
Comparisons between each subgroup were performed using Tukey
post hoc test, and independent samples were analysed using
Student’s t-test. Data are presented as the mean  S.D. P < 0.05
was considered statistically significant.
Table 2 Primary antibodies used for Western blot analysis
Antibody References Company
LRP1 Ab92544 Abcam
pPyk2 #3291 Cell Signaling Technology
Total Pyk2 #3480 Cell Signaling Technology
pERK1,2 #9101 Cell Signaling Technology
Total ERK1,2 KAP-MA001 Assay Design
Troponin T #MS-295-P Thermo Scientific





pPyk2 sc-16824 Santa Cruz Biotechnology
MMP-9 TP221 AMS Biotechnology
pERK1,2 sc-16982 Santa Cruz Biotechnology
MMP-2 TP220 AMS Biotechnology
cTroponin I Ab188877 Abcam
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Results
Lrp1 expression is up-regulated in ischaemic
myocardium at 10 and 21 days after MI
Lrp1 expression levels were analysed by RT-PCR, and LRP1 pro-
tein expression levels in the non-infarct or remote peri-infarct
and infarct regions were determined by Western blotting and
confocal laser microscopy in all experimental groups (1, 10 and
21 days after MI). These analyses demonstrated significant
increases in Lrp1 gene expression (Fig. 1A) and LRP1 protein
levels (Fig. 1B) in the peri-infarct and infarct regions compared
to the non-infarct remote zones at 10 and 21 days after MI.
These results were confirmed by immunofluorescence. Confocal
microscopy images demonstrated dramatic increases in LRP1
levels in the cells forming the scar at 10 and 21 days after MI
(Fig. 1C). Slight LRP1 expression was also observed in the
fibroblasts surrounding the remote cardiomyocytes. Precise colo-
calization of the fibroblast marker vimentin and LRP1 demon-
strated that LRP1 is mostly expressed in cardiac fibroblasts
(Fig. 2).
RT-PCR and Western blot analysis showed that LRP1
mRNA and protein expression levels, respectively, were signifi-
cantly reduced in the infarct zone at 1 day after MI, in con-
trast to the above results (Fig. 1A and B). Immunofluorescence
imaging confirmed the reductions in LRP1 protein levels in the
infarct areas compared to the peri-infarct or remote areas
(Fig. 1C).
pPyk2 and pERK1,2 are signal mediators that are
differentially modulated at both the temporal
level and the spatial level after MI
Western blot analysis showed that both, LRP1 and pPyk2 levels
were significantly down-regulated in the ischaemic zones at 1 day
after MI (Fig. 3A and B). In contrast, pPyk2 expression was
strongly up-regulated in the peri-infarct and infarct areas at
10 days (Fig. 3A and C) and 21 days after MI (Fig. 3A and D).
In addition, pERK1,2 expression was strongly up-regulated in the
infarct areas at 1 (Fig. 3A and E), 10 (Fig. 3A and F) and 21
(Fig. 3A and G) days after MI.
MMP-9 and MMP-2 have a differential temporal
and spatial modulation after MI
Zymography analysis showed that MMP-9 activity was strongly
increased in the infarct areas on day 1 after MI (Fig. 4A and B)
and was moderately increased in the peri-infarct and infarct areas
on day 10 (Fig. 4A and C) and day 21 after MI (Fig. 4A and D)
compared to the remote zone. Differently, MMP-2 activity was
extremely low in all tested zones on day 1 after MI (Fig. 4A and
E). A strong increase in MMP-2 activity was detected in all zones
at 10 days after MI but especially in the infarct area (Fig. 4A and
F). MMP-2 overactivation was slightly maintained at 21 days after
MI (Fig. 4A and G). RT-PCR analysis yielded similar results than
zymography with respect to temporal and spatial MMP-9 (Fig. 6H,
I and J) and MMP-2 (Fig. 6K, L and M) mRNA expression pat-
terns after MI.
MMP-9 colocalized with pPyk2 and LRP1 in the
cardiac fibroblasts of ischaemic myocardium at
10 and 21 days after MI
Confocal microscopy images demonstrated a strong colocalization
among pPyk2, MMP-9 and LRP1 in cardiac fibroblasts in the peri-
infarct and infarct zones at 10 and 21 days after MI (Fig. 5). In
contrast, pERK1,2, which exhibited only slight expression, did not
colocalize with MMP-9 or LRP1 in any zones or stages after MI
(Fig. 6A). Confocal microscopy also demonstrated no colocalization
between MMP-2 and pERK1,2, and only few cells expressed both
LRP1 and MMP-2 in all the areas analysed (Fig. 6B).
We next compared the role of hypoxia on LRP1 levels in cultured
macrophages and fibroblasts. Western blot analysis showed that
hypoxia significantly reduced Pyk2 phosphorylation (Fig. 7A and C)
concomitantly with a decay on LRP1 protein levels (Fig. 7A and B) in
macrophages. In contrast, both LRP1 protein (Fig. 7G and H) and
Pyk2 phosphorylation (Fig. 7G and I) levels were significantly up-
regulated by hypoxia in fibroblasts. Zymography analysis showed that
hypoxia reduces MMP-9 activity in macrophages (Fig. 7D and E) but
induces MMP-9 activity in fibroblasts (Fig. 7J and K). MMP-2 activity
levels were similar in both macrophages (Fig. 7D and F) and fibrob-
lasts (Fig. 7J and L). In addition, we compared the hypoxic effects on
control (Lrp1+/+) and LRP1-deficient (Lrp1/) fibroblasts. As shown
in Figure 8, hypoxia failed to up-regulate LRP1 (Fig. 8A and B) and
Fig. 1 Changes in Lrp1 mRNA and LRP1 protein levels after MI. Frozen myocardial tissue samples ( 40 mg) from the remote, peri-infarct and
infarct zones were homogenized in TriPureTM Reagent. RNA and protein were isolated as explained in the Materials and Methods. (A) RT-PCR show-
ing Lrp1 mRNA expression levels. Data were processed using a specially designed software program based on the Ct values of each sample and
normalized to 18s rRNA, which served as an endogenous control. (B) Representative Western blot analysis results showing LRP1 and troponin T
protein expression and bar graphs showing the mean  S.D. of LRP1 protein bands normalized to troponin T bands. n = 8. *P < 0.05 versus
remote; #P < 0.05 versus peri-infarct; **P < 0.01 versus remote; ##P < 0.01 versus peri-infarct; ***P < 0.005 versus remote. (C) Representative
immunostaining of heart cross sections showing the temporal evolution of LRP1 levels after MI. LRP1 is shown in red, and cTnI, in green. Cell
nuclei were counterstained with DAPI (blue). Scale bars, 20 lm.
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Pyk2 phosphorylation (Fig. 8A and C) in Lrp1/ compared to Lrp1+/+.
Moreover, MMP-9 activity (Fig. 8D and E) was significantly up-regu-
lated by hypoxia in Lrp1+/+ but not in Lrp1/ fibroblasts, indicating
that LRP1 is essential for Pyk2 phosphorylation and MMP-9 activation
in cardiac fibroblasts. MMP-2 activity levels (Fig. 8D and F) were simi-
lar in all tested conditions.
Discussion
LRP1 has been described as a key regulator of extracellular matrix
remodelling [24–28], which is associated with morbidity and mortal-
ity after MI [29–31]; however, no previous studies have analysed the
spatial and temporal evolution of LRP1 after MI. Here, we report for
the first time that the myocardial LRP1 strongly colocalizes with
pPyk2 and MMP-9 during the fibrotic stages of remodelling after MI.
Although it is known that MMP-9 activity plays a key role in remod-
elling after MI, these findings have not successfully facilitated
improvements in human MI management. Our results indicate that
LRP1 is a target for specifically modulating cardiac fibroblast MMP-9
levels during the early stages of fibrosis after MI.
We demonstrated that LRP1 levels are extremely high in car-
diac fibroblasts during the fibrotic states of remodelling after MI.
In contrast, LRP1 was scarcely detected in the infarct areas dur-
ing the inflammatory phase of remodelling after MI, whose main
cellular components are neutrophils and macrophages. We have
previously shown that inflammatory mediators reduce LRP1 levels
in human macrophages through sterol regulatory element-binding
protein (SREBP)-1 up-regulation [32]. The capacity of inflamma-
tory mediators to up-regulate SREBP-1 levels has also been
demonstrated in mouse macrophages [33, 34]. These results
suggest that the inflammatory state characterizing the infarct
Fig. 2 Identification of LRP1-expressing
cells in infarcted heart cross sections.
LRP1 is shown in red; vimentin, in green;
cTnI, in grey; and Lrp1 and vimentin colo-
calization, in yellow. Cell nuclei were
counterstained with DAPI (blue). Scale
bars, 20 lm.
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areas at 1 day after MI may be the cause of the reduced LRP1
levels in neutrophils and macrophages. In addition, macrophages
with low LRP1 levels may contribute to the exacerbation of the
inflammatory process, as it has been previously shown that
macrophage LRP1 deficiency contributes to increased MMP-9,
MCP-1 and TNF-a secretion in atherosclerosis [35]. Additional
studies are required to establish whether the above-mentioned
low inflammatory cell LRP1 levels during the first stage of
remodelling after MI are a cause of inflammation, a consequence
of inflammation, or both. Consistent with the findings of previous
studies [20, 36, 37], we observed high MMP-9 levels in conjunc-
tion with neutrophil and macrophage infiltration during the
inflammatory phase of remodelling after MI. Our confocal micro-
scopy images demonstrated a lack of colocalization between
MMP-9 and LRP1 during the inflammatory phase after MI. Taken
together, these results suggest that the robust MMP-9 activation
observed at 1 day after MI does not depend on LRP1. Remark-
ably, myocardial LRP1 was significantly up-regulated in ischaemic
areas during the fibrotic stages of remodelling after MI in con-
junction with increases in cardiac fibroblast proliferation. It is
well known that cardiac fibroblasts adopt a myofibroblast-like
phenotype in response to specific stimuli and that this acquired
phenotype plays a critical role in remodelling after MI in the
heart [38, 39]. One potent stimulus that triggers the development
of this myofibroblast-like phenotype is hypoxia [40], which is
also a potent inducer of LRP1 expression in hVSMCs [11, 12]
and cardiomyocytes [13, 41]. Therefore, hypoxia may contribute
to significant LRP1 overexpression in cardiac fibroblasts located
in ischaemic areas after MI. It has been previously reported that
LRP1 depletion in fibroblasts inhibits transforming growth factor
beta (TGFb) expression [42, 43]. LRP1 overexpression in cardiac
fibroblasts may thus promote TGFb signalling, a crucial inducer
of the specialized phenotype that fibroblasts acquire in response
to injury [44, 45]. Therefore, LRP1 may act as an integrator of
TGFb and hypoxia signalling in cardiac fibroblasts.
Here, we observed increases in MMP-9 mRNA expression
and activation in the infarct areas at all time points after MI,
consistent with the findings of previous studies [36, 46–48]. Pre-
vious studies conducted by our group showed that the up-regula-
tory effects exerted by hypoxia on LRP1 determine MMP-9
activation and that this mechanism is related to Pyk2 phosphory-
lation in hVSMCs [12]. Using confocal microscopy, we observed
Fig. 3 Temporal and spatial evolution of
myocardial phosphorylated Pyk2 and
ERK1,2 levels after MI. (A) Representative
Western blot analysis showing pPyk2,
total Pyk2, pERK1,2 and total ERK1,2 pro-
tein expression. Bar graphs showing the
mean  S.D. of the pPyk2/total Pyk2 ratio
and the pERK1,2/total ERK1,2 ratio in the
remote, peri-infarct and infarct zones at 1
(B, E), 10 (C, F) and 21 (D, G) days after
MI. n = 8. *P < 0.05 versus remote;
#P < 0.05 versus peri-infarct; **P < 0.01
versus remote; ##P < 0.01 versus peri-
infarct; ***P < 0.005 versus remote;
###P < 0.005 versus peri-infarct.
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high level of colocalization among LRP1, Pyk2 and MMP-9 in
cardiac fibroblasts in the infarct zones at 10 and 21 days after
MI. Western blot analysis demonstrated significant Pyk2 phos-
phorylation up-regulation in the infarct zone at 10 days after MI,
which persisted until 21 days after MI. Consistent with this find-
ing, we observed high MMP-9 expression and activity in the
infarct zone at 10 and 21 days after MI. Factors other than
hypoxia, including interleukin-1a, have been reported to con-
tribute to increases in MMP-9 expression in cardiac fibroblasts
[38, 49–51]. Several factors can modulate Pyk2 and MMP-9
levels in infarct areas independently of LRP1 and hypoxia.
The in vitro results comparing the effects of hypoxia on
LRP1 and pPyk2 levels in macrophages and fibroblasts match
with in vivo studies. On one side, LRP1 and pPyk2 down-reg-
ulation in cultured macrophages exposed to hypoxia fits with
down-regulation of these molecules at early post-infarct stages
(1 day after MI) where the main component is inflammation
and macrophages. On the other hand, LRP1 and pPyk2 up-
regulation in cultured fibroblasts fits with the high levels of
these molecules at later post-infarct stages (10 and 21 days
after MI) where the main component is fibrosis and
fibroblasts. MMP-9 levels were extremely low in cultured
hypoxic macrophages.
The high MMP-9 activation that we have found in infarcted
area at 1 day after MI suggests that inflammatory mediators pre-
sent in vivo overcome the potential down-regulatory effect of
hypoxia on macrophage MMP-9 levels. The activation of MMP-9
levels found in infarcted areas at 10 and 21 days after MI is
coherent with the up-regulatory effect of hypoxia on fibroblast
MMP-9 activation. In agreement, our immunofluorescence imag-
ing results show a high colocalization degree between LRP1,
pPyk2 and MMP-9 at 10 and 21 days after MI. Further, we
Fig. 5 Representative confocal microscopy images showing LRP1, MMP-9 and pPyk2 levels in the remote, peri-infarct and infarct zones after MI.
Immunostaining of heart cross sections showing the temporal evolution of pPyk2, MMP-9 and LRP1 expression levels after MI. LRP1 is shown in
red; MMP-9, in green; and pPyk2, in grey. A and B inserts are amplified in A’ and B’, respectively, to show colocalization of the three markers in
light yellow. Cell nuclei were counterstained with DAPI (blue). Scale bars, 50 lm.
Fig. 4 Temporal and spatial evolution of myocardial MMP-9 and MMP-2 activation and expression after MI. (A) Representative zymography
analysis results showing myocardial MMP-9 and MMP-2 activity. Bar graphs showing the mean  S.D. of MMP-9 and MMP-2 activity in the
remote, peri-infarct and infarct zones at 1 (B and E), 10 (C and F) and 21 (D and G) days after MI. (H–M) Real-time PCR showing MMP-9
and MMP-2 mRNA expression levels. Data were processed using a specially designed software program based on the Ct values of each sam-
ple and normalized to 18s rRNA, which served as an endogenous control. The results are shown as the mean  S.D. of MMP-9 and MMP-2
mRNA expression levels in the remote, peri-infarct and infarct zones at 1 (H and K), 10 (I and L) and 21 (J and M) days after MI. n = 8.
*P < 0.05 versus remote; **P < 0.01 versus remote; ##P < 0.01 versus peri-infarct; ***P < 0.005 versus remote; ###P < 0.005 versus peri-
infarct.
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showed that MMP-9 activation by hypoxia does not take place in
LRP1-deficient fibroblasts. Taken together, our data suggest that
by up-regulating LRP1 in cardiac fibroblasts, hypoxia promotes
pPyk2 phosphorylation and MMP-9 activation in LV remodelling
after MI (summarized in Fig. 8G).
We have previously shown that both LRP1 silencing and PP2,
a Pyk2 phosphorylation inhibitor, abolished hypoxia-induced
MMP-9 overexpression and activation in hVSMCs [12]. We also
showed that in contrast to LRP1 inhibition, PP2 expression did
not alter vascular cell pro-inflammatory phenotypes. PP2-mediated
Pyk2 phosphorylation inhibition has been shown to efficiently
reverse fibrosis development in a load-induced cardiac hypertro-
phy mouse model [52] and to attenuate fibrosis after MI [53].
Here, we showed for the first time the temporal and spatial evo-
lution of pPyk2 levels after MI. Our results suggest that pPyk2
could play a crucial role in up-regulating MMP-9 activity in car-
diac fibroblasts, especially at 10 days after MI. We previously
showed that hypoxia-induced LRP1-pPyk2-NF-kb activation is
important for MMP-9 activation, but not MMP-2 activation [12].
The MMP-9 and MMP-2 promoter elements are very different
[50, 54], suggesting that MMP-9 and MMP-2 are modulated by
different pathways after MI.
Fig. 7 Comparison of the hypoxia impact on LRP1, pPyk2 levels and MMP-9/MMP-2 activation in macrophages and fibroblasts. Quiescent macro-
phages and fibroblasts were exposed to normoxic or hypoxic conditions for 18 hrs. Representative Western blot analysis showing LRP1, pPyk2,
total Pyk2 and b-tubulin bands (A&G). Bar graphs showing the mean  S.D. of LRP1 normalized to b-tubulin levels (B&H) and pPyk2/total Pyk2
ratio (C&I). (D&J) Representative zymography analysis showing MMP-9 and MMP-2 activity and bar graphs showing the mean  S.D. of MMP-9
(E&K) and MMP-2 (F&L) activity levels. Results are shown as the mean  S.E.M. of three independent experiments performed in triplicate.
***P < 0.001 versus normoxia. NO: normoxia; HO: hypoxia.
Fig. 6 Representative confocal microscopy images showing LRP1, MMP-9 and pERK1,2 expression levels in the remote, peri-infarct and infarct
zones after MI. (A) Immunostaining of heart cross sections showing the temporal evolution of pERK1,2 (grey), MMP-9 (green) and LRP1 (red)
expression levels after MI. (B) Immunostaining of heart cross sections showing the temporal evolution of pERK1,2 (grey), MMP-2 (green) and
LRP1 (red) expression levels after MI. Cell nuclei were counterstained with DAPI (blue). Scale bars, 50 lm.
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In conclusion, our results suggest that LRP1 plays a major role in
MMP-9 up-regulation in cardiac fibroblasts after MI and highlight the
potential role of LRP1 modulation for treatment of cardiac remod-
elling.
Clinical implications
It has been consistently demonstrated that MMP activity modifi-
cation is a key mechanism underlying remodelling after MI [55,
56]. However, these results have not successfully facilitated
improvements in human MI management. It has been suggested
that temporal and cell-specific MMP inhibition has therapeutic
potential. LRP1 may enable clinicians to modulate cardiac
fibroblast MMP-9 levels during the early stage of fibrosis
after MI.
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